Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Arrivent Biopharma, Inc.

Clinical trials sponsored by Arrivent Biopharma, Inc., explained in plain language.

ArriVent Biopharma, Inc. AVBP NASDAQ

A clinical-stage biopharmaceutical company developing novel therapies for cancer.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 3 Not yet finished but already full! 1

New hope for Hard-to-Treat lung cancer: targeted drug shows promise in early trial

Disease control Ongoing

This early-stage study tests a new drug called furmonertinib in about 160 people with advanced or spreading non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to see if the drug is safe and can shrink tumors. Participants must have alre…

Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control

Last updated Jun 27, 2026 11:01 UTC